CORRECTION Open Access

Correction to: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial



Bastiaan Maes^{*†}, Cedric Bosteels[†], Elisabeth De Leeuw[†], Jozefien Declercq[†], Karel Van Damme[†], Anja Delporte, Bénédicte Demeyere, Stéfanie Vermeersch, Marnik Vuylsteke, Joren Willaert, Laura Bollé, Yuri Vanbiervliet, Jana Decuypere, Frederick Libeer, Stefaan Vandecasteele, Isabelle Peene and Bart N. Lambrecht

Correction to: Trials (2020) 21:468 https://doi.org/10.1186/s13063-020-04453-5

Following publication of the original article [1], we have been notified that an initial was missed from one of the author names.

Originally published author names:

• Bart Lambrecht

Correct author names:

• Bart N. Lambrecht

The original article has been corrected.

Published online: 22 June 2020

Reference

 Maes, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:468. https://doi.org/10.1186/ s13063-020-04453-5.

The original article can be found online at https://doi.org/10.1186/s13063-020-04453-5.

VIB-UGent Inflammatie-researchcentrum, Oost-Vlaanderen, Ghent, Belgium



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: bastiaan.maes@irc.vib-ugent.be

[†]Bastiaan Maes, Cedric Bosteels, Elisabeth De Leeuw, Jozefien Declercq and Karel Van Damme are joint first authors.